Based on these results, we constructed a A549-bearing mouse model and found that NKG2D(bbz) CAR-T-cell-treated mice exhibited lasting anti-tumor effects with two infusions on day 14 and day 22 (Figures 5E, F). Here, KLRK1 is linked to neoplasm.